Zuellig Pharma Korea, a global drug distribution company, escaped from complete capital impairment last year (total capital was negative). Operating profit also turned to black for the first time in six years. We are concentrating our efforts on improving performance by significantly reducing SG&A. According to the Financial Supervisory Service on the 4th, Zuellig Pharma Korea recorded sales of 885.3 billion won and an operating profit of 900 million won last year. Sales decreased by 2.7% from 909.9 billion won in the previous year, but operating profit turned to black from a deficit of 13.9 billion won. This is the effect of reducing SG&A by more than W10bn. In 2021, Zuellig Pharma Korea spent 94.1 billion won on SG&